Compare VINP & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VINP | CSTL |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.8M | 640.6M |
| IPO Year | 2020 | 2019 |
| Metric | VINP | CSTL |
|---|---|---|
| Price | $9.84 | $24.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $14.00 | ★ $45.50 |
| AVG Volume (30 Days) | 63.3K | ★ 348.7K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $18.07 | $2.42 |
| Revenue Next Year | $12.74 | $12.69 |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $9.20 | $14.59 |
| 52 Week High | $13.61 | $44.28 |
| Indicator | VINP | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 67.93 |
| Support Level | $9.66 | $23.21 |
| Resistance Level | $10.88 | $26.20 |
| Average True Range (ATR) | 0.38 | 0.87 |
| MACD | 0.03 | 0.47 |
| Stochastic Oscillator | 30.66 | 98.00 |
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.